RESEARCH-USE BIOSIMILAR ANTIBODY
Pivekimab
Antibody-drug conjugate · IgG1
Pivekimab is a human IgG1 monoclonal antibody that targets interleukin-3 (IL-3) and CD123. Pivekimab is used to synthesize pivekimab sunirine, a CD123-directed antibody-active molecule conjugate (ADC). Pivekimab is used in the study of blastic plasmacytoid dendritic cell neoplasm (BPDCN).
TARGETIL3RA
YAntibody-drug conjugate
CATALOGSC-BS-271
CATALOG NUMBERSC-BS-271
MOLECULAR WEIGHTApprox. 145.98 kDa
PRODUCT FORMATAntibody-drug conjugate
PRODUCT OVERVIEW
A research-use configuration for comparative antibody studies
Pivekimab is a human IgG1 monoclonal antibody that targets interleukin-3 (IL-3) and CD123. Pivekimab is used to synthesize pivekimab sunirine, a CD123-directed antibody-active molecule conjugate (ADC). Pivekimab is used in the study of blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Pivekimab is a recombinant research-use antibody directed against IL3RA.